Bristol Myers Squibb is working on contingency plans to “protect the continuity of supply” of medicine in preparation for draft US legislation seeking to restrict Chinese pharmaceutical companies over national security concerns, according to its finance chief.The Biosecure Act, introduced in the US Congress in January, would prohibit US companies receiving federal grant money from working with WuXi AppTec and any related entities. Three other Chinese companies are named in the draft legislation, including gene sequencing group BGI Genomics.
百時美施貴寶(Bristol Myers Squibb)的首席財務官表示，該公司正在制定“保護（藥品）供應連續性”的應急預案，以求針對美國出于國家安全擔憂對中國藥企設限的立法草案做好準備。
您已閱讀15%（640字），剩余85%（3694字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。